While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Level Up! An Abstinence Game for Smoking Cessation
Breaking the SABA-only Rescue Habit: Two Drugs Are Better Than One
Are You Sure? Tolerance of Uncertainty and the Risk of Stress-Related Harm
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Educating Patients and Prescribers About Deprescribing to Reduce Medication Burden May Not Be Enough
Treating mild hypertension during pregnancy: Time for a new CHAPter!
Finally! Something FDA-Approvable for Non-alcoholic Steatohepatitis (NASH)?
Managing Pain in Patients with High Blood Pressure: Is There No Safe PATH?
Continuous Glucose Monitors (CGMs) - Patient Management Strategies and Getting Paid!
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Annual Wellness Visits: Pharmacists Closing Care Gaps
FOMO — Keeping Up With the Primary Literature
Could a DOAC Replace Warfarin to Treat the Thrombotic Antiphospholipid Syndrome?
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Don’t Miss a Beat: The Importance of Influenza Vaccination in Patients with Coronary Disease
Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Top Ten Things Every Clinician Should Know about the 2022 Medical Standard of Care for Diabetes
On the Look Out for Prescribing Cascades
Thiazides in Chronic Kidney Disease: New Evidence Challenging Old Dogma
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive